Gene
GLI2
GLI2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (1), Trial mentions (30), Target-disease associations (1,109), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention GLI2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 2 of 8,875 | 0.02% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 2 of 11,460 | 0.02% |
| 2022 | 4 of 8,285 | 0.05% | 5 of 13,598 | 0.04% |
| 2021 | 5 of 8,692 | 0.06% | 3 of 15,045 | 0.02% |
| 2020 | 1 of 7,640 | 0.01% | 3 of 14,459 | 0.02% |
| 2019 | 0 of 7,300 | 0.00% | 7 of 12,159 | 0.06% |
| 2018 | 2 of 6,927 | 0.03% | 6 of 11,854 | 0.05% |
| 2017 | 2 of 6,558 | 0.03% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| GLI2 amplification | Smo Inhibitors | responsive | medulloblastoma | Cancer Genome Interpreter |
Trial mentions (30)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03207113 | Trial eligibility (AACT) |
| NCT04717531 | Trial eligibility (AACT) |
| NCT06548178 | Trial eligibility (AACT) |
| NCT03676985 | Trial eligibility (AACT) |
| NCT07008703 | Trial eligibility (AACT) |
Showing 5 of 30 trial mentions.
Target-disease associations (1,109)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 15q overgrowth syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 2q31.1 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 2q33.1 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 3-M syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| 3C syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 1,109 associations.
Vendor sourcing (132)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Frameshift variant is predicted to result in a loss or disruption of normal protein function throug... | View ClinVar record SCV002572673.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV000603840.7 |
| Alberta Health Services | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. 18 years of age or older 2. Completed curative-intent treatment 3. Receiving PCa survivorship care at University Health Network (UHN), Trillium Health ... | View trial NCT05033301 |
| Alberta Health Services | Trial collaborator | Mentioned in trial textTrial free-text mention | THP | View trial NCT05033301 |
| Alliance for Clinical Trials in Oncology | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : • HER2-positive status will be based on pretreatment biopsy material and defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ h... | View trial NCT04457596 |
Showing 5 of 132 sourcing records.
Trial-cited literature (61)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. | Leukemia | 2023 | 29 |
| Diagnosis and Incidence of Congenital Combined Pituitary Hormone Deficiency in Denmark-A National Observational Study. | The Journal of clinical endocrinology and metabolism | 2023 | 9 |
| Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. | Journal of hematology & oncology | 2022 | 389 |
| The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions. | Biomolecules | 2022 | 81 |
| Integrated multi-omics reveals cellular and molecular interactions governing the invasive niche of basal cell carcinoma. | Nature communications | 2022 | 51 |
Showing 5 of 61 papers.
Protein variant mentions (41)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1139S | 1 | 2015 | PMID 25741868 |
| p.A203T | 1 | 2015 | PMID 25741868 |
| p.A268V | 1 | 2015 | PMID 25741868 |
| p.A459P | 1 | 2015 | PMID 25741868 |
| p.D1289N | 1 | 2015 | PMID 25741868 |
Showing 5 of 41 variants.
Literature-extracted relations (3)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Breast Neoplasms | Disease | associate |
Correlation Between Doppler Ultrasound Blood Flow Parameters and Angiogenesis and Proliferation Activity in Breast Cancer. | 2019 |
| Adrenal Gland Diseases | Disease | associate |
Classical and non-classical causes of GH deficiency in the paediatric age. | 2016 |
| Bronchiolitis Obliterans Syndrome | Disease | stimulate |
Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. | 2012 |
Organizations publishing (100)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 4 | 2010 to 2022 |
| Dana-Farber Cancer Institute | Other | 3 | 2020 to 2021 |
| Harris Health System | Hospital | 3 | 2013 to 2020 |
| Case Western Reserve University | Academic | 2 | 2021 to 2023 |
| Duke University Health System | Academic | 2 | 2015 to 2018 |
Showing 5 of 100 organizations.
Where GLI2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
1,085 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, and human sample screening reference.